---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-001962"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:33:47.663864+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apellis CMO Federico Grossi departs; Caroline Baumal named new CMO effective Jan 3, 2023

## Summary
- Federico Grossi, M.D., Ph.D., leaves as Chief Medical Officer effective Jan 3, 2023 to pursue new career opportunities.
- Caroline Baumal, M.D., appointed CMO effective Jan 3, 2023, succeeding Dr. Grossi.
- Dr. Grossi will continue at Apellis through Feb 28, 2023 to assist transition and pegcetacoplan launch preparations.

## SEC filing metadata
- accession: 0001193125-23-001962
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/0001193125-23-001962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/d436534d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-001962
- JSON: https://secwatch.observer/filing/0001193125-23-001962.json
- Plain text: https://secwatch.observer/filing/0001193125-23-001962.txt

## Key facts
- Executive change
  Federico Grossi departed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..
  - Action: leaving
  - Role: Chief Medical Officer
  source text: Federico Grossi, M.D., Ph.D., the Chief Medical Officer of the Company, will be leaving the Company to pursue new career opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/0001193125-23-001962-index.htm
- Executive change
  Caroline Baumal was appointed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Caroline Baumal, M.D. will join the Company as Chief Medical Officer, effective as of January 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/0001193125-23-001962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.